Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of cell therapy company Cytori Therapeutics (NASDAQ:CYTX) soared a whopping 70% on Tuesday after announcing an Asia-Pacific licensing deal with Lorem Vascular.
So what: The 30-year agreement could bring Cytori up to $531 million in licensing fees, representing a massive chunk of potential revenue for such a small company -- its market cap was only $140 million yesterday. Additionally, Lorem will invest $24 million in Cytori at $3 per share under a product supply agreement, giving analysts even more good vibes over its commercialization prospects going forward.
Now what: Don't expect the operating momentum to slow anytime soon.
"[W]e are uniquely positioned to expand our cell therapy brand by being first-to-market with cell therapy products in new geographies around the world," said Cytori CEO Christopher Calhoun. "Lorem Vascular brings to Cytori the required resources, market knowledge, dedication and focus to commercialize this innovative treatment and pioneer the introduction of cell therapy products for patients with the most serious conditions."
Given today's staggering share-price surge, however, I'd wait for the extreme exuberance to fade before buying into that bull talk.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.